Medical Use
Mektovi is a kinase inhibitor used in combination with encorafenib for treating patients with unresectable or metastatic melanoma that has a BRAF V600E or V600K mutation.
Recommended Dosage: Take 45 mg of Mektovi orally twice daily, approximately 12 hours apart, alongside encorafenib. Continue treatment until disease progression or unacceptable toxicity occurs.
Administration Instructions: Mektovi tablets can be taken with or without food. If a dose is missed, do not take it within 6 hours of the next scheduled dose. If vomiting occurs after taking a dose, do not take an extra dose; simply continue with the next scheduled dose.
Important Note: Confirm the presence of a BRAF V600E or V600K mutation in tumor specimens before starting Mektovi treatment.
Warning & Precautions
Cardiomyopathy, presenting as left ventricular dysfunction (LVD) with symptomatic or asymptomatic reductions in ejection fraction, may occur in patients treated with Mektovi 15 mg tablets in combination with encorafenib. Evaluate ejection fraction using echocardiogram or MUGA scan before starting therapy, one month after initiation, and then every 2-3 months during treatment. Patients with cardiovascular risk factors should be closely monitored when treated with Mektovi.
Venous Thromboembolism (VTE), including pulmonary embolism, may occur in patients receiving binimetinib along with encorafenib. Depending on the severity of side effects, withhold, reduce the dose, or permanently discontinue treatment.
Serous Retinopathy may occur in patients treated with binimetinib 15 mg tablets along with encorafenib. Evaluate for visual symptoms at each visit and perform regular ophthalmologic assessments for new or worsening visual disturbances and to monitor new or persistent findings.
Retinal Vein Occlusion (RVO) is a known class-related side effect of MEK inhibitors and may occur in patients treated with binimetinib along with encorafenib. Perform an ophthalmologic examination within 24 hours for any patient-reported acute vision loss or other visual disturbances. Permanently discontinue the drug in patients with documented RVO.
Uveitis, including iridocyclitis and iritis, may occur in patients treated with binimetinib in combination with encorafenib. Assess visual symptoms at each visit and perform regular ophthalmologic assessments.
Patients with BRAF mutation-positive melanoma receiving binimetinib 15 mg tablets along with encorafenib may develop Interstitial Lung Disease (ILD), including pneumonitis. Assess new or progressive unexplained pulmonary signs and symptoms for possible ILD. Withhold, reduce the dose, or permanently discontinue treatment based on the severity of side effects.
Hepatotoxicity: When binimetinib is administered with encorafenib, there is a risk of hepatotoxicity. It is essential to monitor liver laboratory tests before starting therapy and monthly throughout the treatment. Depending on the severity of side effects, the dose should be withheld, reduced, or permanently discontinued.
Rhabdomyolysis: The combination of Mektovi (binimetinib) and encorafenib may lead to rhabdomyolysis. Monitor CPK and creatinine levels before starting Mektovi 15 mg tablets and periodically during treatment. Adjust the dose or discontinue use based on the severity of side effects.
Fetal Harm: Mektovi can cause fetal harm if administered to pregnant women. Women of reproductive age should use effective contraception during treatment and for at least 30 days after the last dose.
Documentation Availability
Documents required to import MEKTOVI to India?
MEKTOVI (Binimetinib) can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing MEKTOVI from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the Generic Name for the trade name drug Mektovi®?
Binimetinib is Generic Name for the trade name drug Mektovi®.
What is the Manufacturer Name of Mektovi®?
Mektovi® is manufactured by Array BioPharma Inc.
Is Mektovi® approved by the FDA?
Yes, Mektovi® is approved by the FDA. Date of first/initial approval: June 27, 2018.
Where can I get Mektovi® 15 mg at the best price in India?
To get the best Mektovi 15 mg tablets price in India, order from www. rx4u.in
What is the dosage and form of Mektovi® supplied?
Mektovi® is supplied as Tablets: 15 mg for oral administration.
What are the most common side effects for Mektovi®?
The most common side effects for Mektovi along with medicine encorafenib, are fatigue, vomiting, nausea, diarrhea, and abdominal pain.
How much does Mektovi® cost in India?
The mektovi cost in India is less and can vary. To procure this melanoma medication authentically, reach out to Rx4U team
What are the storage conditions of Mektovi®?
Mektovi (binimetinib) is formulated as 15 mg yellow-dark yellow, oval film-coated tablets. Store tablets at 20-25°C (68-77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).
Is it safe to buy Mektovi® online from India?
Yes, You can buy Mektovi tablets in India online at the best price Rx4u team.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
